Approximately 10% of HIV-positive patients are coinfected with HBV. EACS guidelines suggest life-long use of tenofovir (TDF/TAF) or entecavir (ENT); caution in NRTI substitutions is advised since drugs with lower genetic barrier (lamivudine/emtricitabine [XTC]) may favour the selection of resistance and the occurrence of hepatic flares. The long-term outcome of anti-HBV strategies in HIVpositive patients is poorly known.
Long-term follow-up of HIV-HBV co-infected patients according to the use of anti-HBV active drugs
G. Nunnari;G. F. Pellicanò
2018-01-01
Abstract
Approximately 10% of HIV-positive patients are coinfected with HBV. EACS guidelines suggest life-long use of tenofovir (TDF/TAF) or entecavir (ENT); caution in NRTI substitutions is advised since drugs with lower genetic barrier (lamivudine/emtricitabine [XTC]) may favour the selection of resistance and the occurrence of hepatic flares. The long-term outcome of anti-HBV strategies in HIVpositive patients is poorly known.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
